Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor.
Metastatic renal cell carcinoma
Overall survival
Predictive factor
Tyrosine kinase inhibitor
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
16
03
2020
accepted:
06
04
2020
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
ppublish
Résumé
There are various alternative first-line therapeutic options besides tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). To inform therapeutic decision-making for such patients, this study aimed to identify predictive factors for resistance to TKI. A total of 239 cases of mRCC patients who received first-line TKI therapy were retrospectively studied. Patients with a radiologic diagnosis of progressive disease within 3 months after initiating therapy were classified as primary refractory cases; the others were classified as non-primary refractory cases. The association between primary refractory cases and age, gender, pathology findings, serum c-reactive protein (CRP) level, metastatic organ status, and 6 parameters defined by the International Metastatic Renal Cell Carcinoma Database Consortium were analyzed. Of 239 cases, 32 (13.3%) received a radiologic diagnosis of progressive disease within 3 months after initiating therapy. The rates of sarcomatoid differentiation, hypercalcemia, a serum CRP level of 0.3 mg/dL or higher, presence of liver metastasis, anemia, and time from diagnosis to treatment interval of less than a year were significantly higher in the primary refractory group. Multivariate analysis showed that sarcomatoid differentiation, hypercalcemia, a serum CRP level of 0.3 mg/dL or higher, and liver metastasis were independently associated with primary refractory disease. A risk-stratified model based upon the number of patients with these factors indicated rates of primary refractory disease of 4.0%, 10.1%, and 45.0% for patients with 0, 1, and 2 or more factors, respectively. Sarcomatoid differentiation, hypercalcemia, an elevated serum CRP level, and presence of liver metastasis were associated with primary refractory disease in mRCC patients receiving first-line TKI therapy. These results provide clinicians with useful information when selecting a first-line therapeutic option for mRCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
There are various alternative first-line therapeutic options besides tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). To inform therapeutic decision-making for such patients, this study aimed to identify predictive factors for resistance to TKI.
MATERIALS AND METHODS
METHODS
A total of 239 cases of mRCC patients who received first-line TKI therapy were retrospectively studied. Patients with a radiologic diagnosis of progressive disease within 3 months after initiating therapy were classified as primary refractory cases; the others were classified as non-primary refractory cases. The association between primary refractory cases and age, gender, pathology findings, serum c-reactive protein (CRP) level, metastatic organ status, and 6 parameters defined by the International Metastatic Renal Cell Carcinoma Database Consortium were analyzed.
RESULTS
RESULTS
Of 239 cases, 32 (13.3%) received a radiologic diagnosis of progressive disease within 3 months after initiating therapy. The rates of sarcomatoid differentiation, hypercalcemia, a serum CRP level of 0.3 mg/dL or higher, presence of liver metastasis, anemia, and time from diagnosis to treatment interval of less than a year were significantly higher in the primary refractory group. Multivariate analysis showed that sarcomatoid differentiation, hypercalcemia, a serum CRP level of 0.3 mg/dL or higher, and liver metastasis were independently associated with primary refractory disease. A risk-stratified model based upon the number of patients with these factors indicated rates of primary refractory disease of 4.0%, 10.1%, and 45.0% for patients with 0, 1, and 2 or more factors, respectively.
CONCLUSIONS
CONCLUSIONS
Sarcomatoid differentiation, hypercalcemia, an elevated serum CRP level, and presence of liver metastasis were associated with primary refractory disease in mRCC patients receiving first-line TKI therapy. These results provide clinicians with useful information when selecting a first-line therapeutic option for mRCC patients.
Identifiants
pubmed: 35069080
doi: 10.1097/CU9.0000000000000042
pii: CURR-UROL-21-0167
pmc: PMC8772668
doi:
Types de publication
Journal Article
Langues
eng
Pagination
187-192Informations de copyright
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Jun Teishima has received lecture fees from Pfizer Inc. and Novartis Pharma Inc.
Références
Urol Oncol. 2017 Nov;35(11):662.e1-662.e7
pubmed: 28778585
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Clin Genitourin Cancer. 2020 Apr;18(2):e83-e90
pubmed: 31753738
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Oncol Lett. 2014 Aug;8(2):881-885
pubmed: 25013512
N Engl J Med. 2007 Jan 11;356(2):125-34
pubmed: 17215530
PLoS One. 2013 May 03;8(5):e63341
pubmed: 23658823
Clin Genitourin Cancer. 2017 Aug;15(4):e573-e582
pubmed: 28139444
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2013 Aug 22;369(8):722-31
pubmed: 23964934
Lancet. 2007 Dec 22;370(9605):2103-11
pubmed: 18156031
Target Oncol. 2014 Sep;9(3):183-93
pubmed: 24243495
Clin Genitourin Cancer. 2018 Jun;16(3):e577-e586
pubmed: 29395949
J Urol. 2014 Mar;191(3):611-8
pubmed: 24018239
BJU Int. 2016 Jun;117(6B):E67-74
pubmed: 26305535
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Clin Cancer Res. 2019 Jul 1;25(13):3839-3846
pubmed: 30967420
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Ann Oncol. 2012 Jun;23(6):1549-55
pubmed: 22056973
Eur Urol. 2015 May;67(5):952-8
pubmed: 25577718
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
J Oncol. 2010;2010:835680
pubmed: 20224655
Int J Urol. 2019 Jun;26(6):608-617
pubmed: 30959579
N Engl J Med. 2019 Mar 21;380(12):1103-1115
pubmed: 30779531
Eur J Cancer. 2012 May;48(7):1023-30
pubmed: 22436979
Cancer Sci. 2015 May;106(5):618-26
pubmed: 25711777
Int J Urol. 2019 Nov;26(11):1076-1077
pubmed: 31368187
J Clin Oncol. 2010 May 1;28(13):2137-43
pubmed: 20368558
J Oncol Pharm Pract. 2018 Dec;24(8):574-583
pubmed: 28732453